NCT00820768 2018-04-11
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Celgene
Phase 1 Withdrawn
Clinical Trials
20 trialsNCT00514371 2015-12-07
TIME-2
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00773344 2015-11-04
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00779428 2015-10-12
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Bristol-Myers Squibb
Phase 2 Completed
NCT00724425 2015-04-15
A Phase 1 Dose Escalation Study of IPI-493
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT01193491 2015-04-15
Dose Escalation of IPI-493 in Hematologic Malignancies
Infinity Pharmaceuticals, Inc.
Phase 1 Terminated
NCT00969917 2015-04-14
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Infinity Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01427946 2014-11-13
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00564928 2012-12-11
IPI-504-04
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00688766 2012-12-11
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Infinity Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00817362 2012-12-11
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00431015 2012-12-10
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00606814 2012-03-06
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
Infinity Pharmaceuticals, Inc.
Phase 1 Completed
NCT00546780 2011-06-28
BMS TIME-1
Bristol-Myers Squibb
Phase 3 Completed
NCT00276302 2011-01-06
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Infinity Pharmaceuticals, Inc.
Phase 1 Completed
NCT00319930 2010-03-08
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Biogen
Phase 1 Terminated
NCT00627627 2010-02-03
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
MedImmune LLC
Phase 1/2 Withdrawn
NCT00113204 2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1 Completed